Skip to Content

Label Changes for:

Cubicin (Daptomycin) for Injection

November 2013

Changes have been made to the ADVERSE REACTIONS sections of the safety label.

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER)  


November 2013


Post-Marketing Experience – Immune System Disorders
  • angioedema and drug rash with eosinophilia and systemic symptoms (DRESS)



May 2012


8.3 Nursing Mothers
  • Daptomycin is present in human milk but is poorly bioavailable orally. In a single case study, CUBICIN was administered daily for 28 days to a nursing mother at an IV dose of 6.7 mg/kg/day, and samples of the patient’s breast milk were collected over a 24-hour period on day 27.  ... Caution should be exercised when CUBICIN is administered to a nursing woman. 


December 2010



Post-Marketing Experience
  • Infections and Infestations: Clostridium difficile-associated diarrhea


August 2010



Eosinophilic pneumonia
  • Eosinophilic pneumonia has been reported in patients receiving Cubicin. In reported cases, patients developed fever, shortness of breath with increased oxygen requirement, and progressive pulmonary infiltrates. In general, patients developed eosinophilic pneumonia 2-4 weeks after starting Cubicin and improved when Cubicin was discontinued and steroid therapy was initiated. In cases where patients were rechallenged with Cubicin, eosinophilic pneumonia recurred. Patients developing these signs and symptoms on Cubicin should undergo prompt medical evaluation and Cubicin should be discontinued immediately. Treatment with systemic steroids should be considered if clinically indicated.



Post-Marketing Experience
  • Respiratory, thoracic and mediastinal disorders: Eosinophilic pneumonia